Celecoxib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Inclusion Criteria:

• Histologically confirmed non-small cell lung cancer
• Stage IIIB or IV disease
• Radiographically measurable disease
• 18 and over
• Performance status: ECOG 0-2
• Renal: Creatinine ≤ 2 mg/dL
• Negative pregnancy test
• Fertile patients must use effective contraception
• More than 4 weeks since prior chemotherapy
• Endocrine therapy: More than 4 weeks since prior corticosteroids; No concurrent corticosteroids, including chronic corticosteroids, except for medically-indicated topical steroids
• Radiotherapy: More than 4 weeks since prior radiotherapy
• More than 4 weeks since other prior anticancer therapy
• More than 4 weeks since prior non-cytotoxic investigational agents
• At least 72 hours since prior nonsteroidal anti-inflammatory drugs (NSAIDs)

Exclusion Criteria:

• pregnant or nursing
• comorbid disease, psychiatric condition, chronic medical condition, or laboratory abnormality that would preclude study treatment or compliance with study requirements
• hypersensitivity to celecoxib, sulfonamides, aspirin, other NSAIDs, or any study reagent
• history of gastrointestinal ulceration, bleeding, or perforation
• other concurrent cyclooxygenase-2 or -3 inhibitors
• other concurrent NSAIDs